2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
10
Urinary Incontinence
2
Sexual Dysfunction, Physiological
2
Melanoma
2
Carcinoma, Transitional Cell
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Secondary Malignant Neoplasm of Bone
1
Sarcoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Esophageal Neoplasms
1
Erectile Dysfunction
1
Desmoid Tumors
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
29
avelumab
21
Nivolumab
20
Ipilimumab
10
Radiotherapy
9
Cyclophosphamide
9
atezolizumab
8
cemiplimab
7
fludarabine
6
Specimen Handling
6
durvalumab
5
aldesleukin
5
Radiation
5
Magnetic Resonance Spectroscopy
5
Interleukin-2
5
Biopsy
5
talimogene laherparepvec
4
ALT-803
4
poly ICLC
3
Radiosurgery
3
Etoposide
3
Cisplatin
3
Carboplatin
3
CTLA-4 Antigen
3
Bevacizumab
3
prednylidene
2
lutetium Lu 177 dotatate
2
fludarabine phosphate
2
domatinostat
2
deltacortene
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Merkel Cell
×
High-Intensity Focused Ultrasound Ablation
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled